应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PTCT PTC Therapeutics Inc.
交易中 11-22 15:18:48 EST
43.66
+0.77
+1.78%
最高
44.10
最低
42.74
成交量
25.50万
今开
43.03
昨收
42.89
日振幅
3.17%
总市值
33.67亿
流通市值
26.50亿
总股本
7,713万
成交额
1,111万
换手率
0.42%
流通股本
6,071万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
美国研究综述-Equifax、Microstrategy、Netflix
路透中文 · 11-19
美国研究综述-Equifax、Microstrategy、Netflix
Ptc Therapeutics, Inc.2024财年第三财季实现净利润-1.07亿美元,同比增加19.55%
市场透视 · 11-17
Ptc Therapeutics, Inc.2024财年第三财季实现净利润-1.07亿美元,同比增加19.55%
BUZZ-PTC Therapeutics 因其基因疗法获 FDA 批准而上涨
路透中文 · 11-14
BUZZ-PTC Therapeutics 因其基因疗法获 FDA 批准而上涨
美国 FDA 批准 PTC Therapeutics 用于治疗超罕见疾病的基因疗法
路透中文 · 11-14
美国 FDA 批准 PTC Therapeutics 用于治疗超罕见疾病的基因疗法
Ptc Therapeutics, Inc.盘中异动 早盘快速拉升6.24%报45.64美元
市场透视 · 11-08
Ptc Therapeutics, Inc.盘中异动 早盘快速拉升6.24%报45.64美元
Ptc Therapeutics, Inc.盘中异动 早盘大幅拉升5.55%报43.14美元
市场透视 · 11-06
Ptc Therapeutics, Inc.盘中异动 早盘大幅拉升5.55%报43.14美元
PTC Therapeutics Inc 预计每股亏损 1.44 美元 - 财报前瞻
Reuters · 11-06
PTC Therapeutics Inc 预计每股亏损 1.44 美元 - 财报前瞻
Ptc Therapeutics, Inc.盘中异动 临近收盘急速拉升5.00%报42.51美元
市场透视 · 10-30
Ptc Therapeutics, Inc.盘中异动 临近收盘急速拉升5.00%报42.51美元
PTC Therapeutics Inc 预计每股亏损 1.44 美元 - 财报前瞻
Reuters · 10-22
PTC Therapeutics Inc 预计每股亏损 1.44 美元 - 财报前瞻
Ptc Therapeutics, Inc.盘中异动 股价大涨5.23%
市场透视 · 10-08
Ptc Therapeutics, Inc.盘中异动 股价大涨5.23%
更新版 3-罕见病药物试验获胜,岩石学者股价暴涨 300
路透中文 · 10-07
更新版 3-罕见病药物试验获胜,岩石学者股价暴涨 300
Ptc Therapeutics, Inc.盘中异动 股价大涨5.13%报38.52美元
市场透视 · 09-27
Ptc Therapeutics, Inc.盘中异动 股价大涨5.13%报38.52美元
Ptc Therapeutics, Inc.2024财年第二财季实现净利润-99.18百万美元,同比增加50.16%
自选股智能写手 · 08-17
Ptc Therapeutics, Inc.2024财年第二财季实现净利润-99.18百万美元,同比增加50.16%
Ptc Therapeutics, Inc.盘中异动 股价大跌5.73%报30.59美元
自选股智能写手 · 08-09
Ptc Therapeutics, Inc.盘中异动 股价大跌5.73%报30.59美元
Ptc Therapeutics, Inc.盘中异动 早盘快速跳水5.37%
自选股智能写手 · 08-05
Ptc Therapeutics, Inc.盘中异动 早盘快速跳水5.37%
Ptc Therapeutics, Inc.盘中异动 股价大跌5.12%报32.44美元
自选股智能写手 · 07-19
Ptc Therapeutics, Inc.盘中异动 股价大跌5.12%报32.44美元
坎托菲茨杰拉德公司:重申PTC Therapeutics(PTCT.US)评级,由增持调整至增持评级, 目标价由62.00美元调整至62.
智通财经 · 07-16
坎托菲茨杰拉德公司:重申PTC Therapeutics(PTCT.US)评级,由增持调整至增持评级, 目标价由62.00美元调整至62.
坎托菲茨杰拉德公司:维持PTC Therapeutics(PTCT.US)评级,由增持调整至增持评级, 目标价由52.00美元调整至62.
智通财经 · 07-01
坎托菲茨杰拉德公司:维持PTC Therapeutics(PTCT.US)评级,由增持调整至增持评级, 目标价由52.00美元调整至62.
美国研究综述-AT&T, ATI, 加利福尼亚资源公司
Reuters · 07-01
美国研究综述-AT&T, ATI, 加利福尼亚资源公司
Ptc Therapeutics, Inc.股价重挫15.20% 市值跌3.43亿美元
自选股智能写手 · 06-28
Ptc Therapeutics, Inc.股价重挫15.20% 市值跌3.43亿美元
加载更多
公司概况
公司名称:
PTC Therapeutics Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Ptc Therapeutics, Inc.于1998年3月31日注册成立为一家特拉华州公司。 PTC Therapeutics股份有限公司是一家生物制药公司,专注于用于转录后控制过程中的口服药,专有的小分子药物的发现和开发。同时该公司的研发计划针对于多个治疗领域,公司特别专注于孤儿和超孤儿混乱疾病的治疗的开发和商业化。公司主导的候选产品是ataluren,该产品用于治疗过程中所出现的一种被称为无义突变基因突变的遗传性疾病的治疗。
发行价格:
--
{"stockData":{"symbol":"PTCT","market":"US","secType":"STK","nameCN":"PTC Therapeutics Inc.","latestPrice":43.655,"timestamp":1732306721578,"preClose":42.89,"halted":0,"volume":255032,"delay":0,"floatShares":60711046,"shares":77125143,"eps":-5.931042,"marketStatus":"交易中","marketStatusCode":2,"change":0.765,"latestTime":"11-22 15:18:48 EST","open":43.03,"high":44.1,"low":42.74,"amount":11108089.121375998,"amplitude":0.031709,"askPrice":43.69,"askSize":304,"bidPrice":43.63,"bidSize":11,"shortable":3,"etf":0,"ttmEps":-5.931042,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732309200000},"adr":0,"listingDate":1371700800000,"adjPreClose":42.89,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":43.13,"preClose":42.89,"latestTime":"09:29 EST","volume":167,"amount":7194.930472,"timestamp":1732285799999},"postHourTrading":{"tag":"盘后","latestPrice":42.89,"preClose":42.89,"latestTime":"16:20 EST","volume":17516,"amount":751261.24,"timestamp":1732224041364},"volumeRatio":0.393718,"impliedVol":0.6368,"impliedVolPercentile":0.4484},"requestUrl":"/m/hq/s/PTCT","defaultTab":"news","newsList":[{"id":"2484960389","title":"美国研究综述-Equifax、Microstrategy、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2484960389","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484960389?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:10","pubTimestamp":1732000212,"startTime":"0","endTime":"0","summary":"美国研究综述-Equifax、Microstrategy、Netflix路透11月19日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括 Equifax、Microstrategy 和 Netflix。要闻 * 凯斯百货公司CASY.O:杰富瑞将目标价从 450 美元上调至 470 美元 * Equifax Inc EFX.N:摩根大通将目标价从304美元下调至283美元 * Microstrategy Inc MSTR.O:Benchmark将目标价从300美元上调至450美元 * Netflix Inc NFLX.O:杰富瑞将目标价从800美元上调至1000美元 * Palo Alto Networks Inc PANW.O:杰富瑞将目标价从400美元上调至450美元以下是路透周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nL4S3MQ0JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LOVE","LU1670710661.SGD","LU0109394709.USD","LU1046421795.USD","LU1429558221.USD","KMPR","BK4585","CCCC","KHC","CASY","ACRS","MEOH","MOS","RDDT","WSM","BK4077","CGEM","FNV","LU2326559502.SGD","ARVN","CHPT","PANW","BK4588","MSTR","NFLX","PLUG","VRT","BK4113","LU1571399168.USD","MRNA","CPRT","RGNX","PTCT","FTNT","EHAB","CPRX","KYMR","BECN","QS","LU2249611893.SGD","FENC","LU0106261372.USD","RC","EFX","IDYA","DCOM","LU2237957902.USD","BK4107","IE00BQXX3C00.GBP"],"gpt_icon":1},{"id":"2484404510","title":"Ptc Therapeutics, Inc.2024财年第三财季实现净利润-1.07亿美元,同比增加19.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484404510","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484404510?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:02","pubTimestamp":1731772933,"startTime":"0","endTime":"0","summary":"11月17日,Ptc Therapeutics, Inc.公布财报,公告显示公司2024财年第三财季净利润为-1.07亿美元,同比增加19.55%;其中营业收入为1.97亿美元,同比增加0.00%,每股基本收益为-1.39美元。从资产负债表来看,Ptc Therapeutics, Inc.总负债28.97亿美元,其中短期债务16.76百万美元,资产负债比为0.64,流动比率为2.10。机构评级:截至2024年11月17日,当前有14家机构对Ptc Therapeutics, Inc.目标价做出预测,其中目标均价为44.21美元,其中最低目标价为26.00美元,最高目标价为66.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000313a23e063c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000313a23e063c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTCT","LENZ"],"gpt_icon":0},{"id":"2483198875","title":"BUZZ-PTC Therapeutics 因其基因疗法获 FDA 批准而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2483198875","media":"路透中文","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483198875?lang=zh_cn&edition=full","pubTime":"2024-11-14 19:54","pubTimestamp":1731585257,"startTime":"0","endTime":"0","summary":"11月14日 - ** 制药商PTC Therapeutics PTCT.O股价盘前上涨3.3%,报45.50美元 ** 本周三,美国食品和药物管理局批准了 PTCT 的基因疗法 Kebilidi,用于治疗一种可能致命的酶缺乏症--芳香族 L-氨基酸脱羧酶 缺乏症。** 鉴于 AADC 患者人数有限,William Blair 分析师预计 2026 年产品收入峰值为 2.663 亿美元。** AADC 缺乏症是一种遗传性疾病,会影响大脑产生多巴胺和血清素的能力,而多巴胺和血清素对运动功能至关重要。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL4S3ML16T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","PTCT","BK4139"],"gpt_icon":0},{"id":"2483320861","title":"美国 FDA 批准 PTC Therapeutics 用于治疗超罕见疾病的基因疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2483320861","media":"路透中文","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483320861?lang=zh_cn&edition=full","pubTime":"2024-11-14 07:06","pubTimestamp":1731539186,"startTime":"0","endTime":"0","summary":"美国 FDA 批准 PTC Therapeutics 用于治疗超罕见疾病的基因疗法路透11月13日 - PTC Therapeutics公司周三表示,美国食品和药物管理局批准了该公司的PTCT.O基因疗法,该疗法可直接在大脑中施用,用于治疗一种潜在的致命性酶缺乏症。(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL4T3MK28E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4139","PTCT","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2481010241","title":"Ptc Therapeutics, Inc.盘中异动 早盘快速拉升6.24%报45.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481010241","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481010241?lang=zh_cn&edition=full","pubTime":"2024-11-08 22:31","pubTimestamp":1731076293,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日22时31分,Ptc Therapeutics, Inc.股票出现异动,股价快速拉升6.24%。Ptc Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.56%。其相关个股中,Fortrea Holdings Inc.、Poseida Therapeutics, Inc.、Tc Biopharm Plc C/Wts 10/02/2028 涨幅较大,Elevai Labs, Inc.、Matinas Biopharma Holdings, Inc.、Lipella Pharmaceuticals Inc.较为活跃,换手率分别为371.30%、16.25%、13.55%,振幅较大的相关个股有Anebulo Pharmaceuticals, Inc.、Cardiff Oncology, Inc.、Sab Biotherapeutics, Inc.,振幅分别为14.96%、13.20%、11.62%。Ptc Therapeutics, Inc.公司简介:PTC Therapeutics Inc 是一家生物制药公司,专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822313395bdeed4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822313395bdeed4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PTCT","BK4139","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2481434985","title":"Ptc Therapeutics, Inc.盘中异动 早盘大幅拉升5.55%报43.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481434985","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481434985?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:31","pubTimestamp":1730903505,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时31分,Ptc Therapeutics, Inc.股票出现异动,股价急速上涨5.55%。Ptc Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.91%。其相关个股中,Sonnet Biotherapeutics Holdings, Inc.、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大,Sonnet Biotherapeutics Holdings, Inc.、Elevai Labs, Inc.、Zyversa Therapeutics, Inc.较为活跃,换手率分别为1028.05%、98.18%、48.89%,振幅较大的相关个股有Vaxcyte, Inc.、Fate Therapeutics, Inc.、Nurix Therapeutics, Inc.,振幅分别为107.85%、107.84%、106.06%。Ptc Therapeutics, Inc.公司简介:PTC Therapeutics Inc 是一家生物制药公司,专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223145971a4bb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223145971a4bb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PTCT","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","LENZ"],"gpt_icon":0},{"id":"2481461143","title":"PTC Therapeutics Inc 预计每股亏损 1.44 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2481461143","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481461143?lang=zh_cn&edition=full","pubTime":"2024-11-06 12:43","pubTimestamp":1730868235,"startTime":"0","endTime":"0","summary":" * PTC Therapeutics Inc 11月7日公布的截至2024年9月30日的财报显示,该公司的季度收入预计将出现下降。* 根据LSEG的数据,13位分析师的平均预期显示,这家总部位于新泽西州沃伦的公司的营收将从去年同期的1.9658亿美元降至1.72655亿美元,降幅为12.2%。* LSEG 分析师对 PTC Therapeutics Inc 的平均预期是每股亏损 1.44 美元。* 华尔街对 PTC Therapeutics Inc 的 12 个月目标价中位数为 37.00 美元,低于其上次收盘价 40.87 美元。11月6日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTC","LENZ","PTCT"],"gpt_icon":0},{"id":"2479052259","title":"Ptc Therapeutics, Inc.盘中异动 临近收盘急速拉升5.00%报42.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479052259","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479052259?lang=zh_cn&edition=full","pubTime":"2024-10-30 04:01","pubTimestamp":1730232067,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日04时01分,Ptc Therapeutics, Inc.股票出现异动,股价急速上涨5.00%。Ptc Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.27%。其相关个股中,Glycomimetics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Surrozen Inc C/Wts 01/08/2031 涨幅较大,Glycomimetics, Inc.、Lixte Biotechnology Holdings, Inc.、Novabay Pharmaceuticals, Inc.较为活跃,换手率分别为1716.99%、1451.22%、363.33%,振幅较大的相关个股有Glycomimetics, Inc.、Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Surrozen Inc C/Wts 01/08/2031 ,振幅分别为183.65%、88.24%、80.85%。Ptc Therapeutics, Inc.公司简介:PTC Therapeutics Inc 是一家生物制药公司,专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103004010798e3f2db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103004010798e3f2db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LENZ","LU0320765992.SGD","LU0109394709.USD","PTCT","BK4139"],"gpt_icon":0},{"id":"2477330900","title":"PTC Therapeutics Inc 预计每股亏损 1.44 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2477330900","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477330900?lang=zh_cn&edition=full","pubTime":"2024-10-22 21:59","pubTimestamp":1729605594,"startTime":"0","endTime":"0","summary":" * PTC Therapeutics Inc 预计在10月24日公布截至2024年9月30日的业绩报告时将出现季度收入下降(预计) * 根据LSEG的数据,12位分析师的平均预期显示,这家总部位于新泽西州沃伦的公司的营收将从去年同期的1.9658亿美元降至1.73306亿美元,降幅为11.8%。* LSEG 分析师对 PTC Therapeutics Inc 的平均预期是每股亏损 1.44 美元。* 华尔街对 PTC Therapeutics Inc 的 12 个月目标价中位数为 37.00 美元,低于其最新收盘价 38.44 美元。10月22日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTCT","LENZ","PTC"],"gpt_icon":0},{"id":"2473751234","title":"Ptc Therapeutics, Inc.盘中异动 股价大涨5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2473751234","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473751234?lang=zh_cn&edition=full","pubTime":"2024-10-08 21:43","pubTimestamp":1728395011,"startTime":"0","endTime":"0","summary":"北京时间2024年10月08日21时43分,Ptc Therapeutics, Inc.股票出现异动,股价快速拉升5.23%。Ptc Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.49%。其相关个股中,Bio-Path Holdings, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Virios Therapeutics, Inc.涨幅较大,Virios Therapeutics, Inc.、Aditxt, Inc.、Bio-Path Holdings, Inc.较为活跃,换手率分别为2884.40%、2024.41%、1668.53%,振幅较大的相关个股有Bio-Path Holdings, Inc.、Aditxt, Inc.、Virios Therapeutics, Inc.,振幅分别为28.18%、25.50%、25.24%。Ptc Therapeutics, Inc.公司简介:PTC Therapeutics Inc 是一家生物制药公司,专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100821433198e3b2cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100821433198e3b2cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTCT","LU0109394709.USD","BK4139","LU0889565916.HKD","LU0320765992.SGD","LENZ"],"gpt_icon":0},{"id":"2473104181","title":"更新版 3-罕见病药物试验获胜,岩石学者股价暴涨 300","url":"https://stock-news.laohu8.com/highlight/detail?id=2473104181","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473104181?lang=zh_cn&edition=full","pubTime":"2024-10-07 19:21","pubTimestamp":1728300064,"startTime":"0","endTime":"0","summary":"更新版 3-罕见病药物试验获胜,岩石学者股价暴涨 300在第 6 和第 7 段添加分析师评论,在第 5 和第 8 段添加类似药物,更新股价Christy Santhosh路透10月7日 - 学岩生物技术公司SRRK.O周一表示,该公司的试验性药物在一项治疗脊髓性肌肉萎缩症的后期试验中达到了主要目标,使其股价在早盘交易中飙升了300%以上。Scholar Rock公司预计将在2025年第一季度申请美国食品药品管理局的批准。截至上周五收盘时的 7.42 美元,该股今年已贬值 60.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241007:nL4S3LJ0S2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0094547139.USD","LU1057294990.SGD","LU0320765992.SGD","BK4516","BK4533","LU0096364046.USD","LU0354030438.USD","LU0061475181.USD","LU1023059063.AUD","LU0708995401.HKD","LU0097036916.USD","LU1093756325.SGD","LU0354030511.USD","PTCT","LU0114720955.EUR","LU0079474960.USD","LU0820561909.HKD","BK4007","LU0058720904.USD","IE00BJLML261.HKD","BHVN","IE0002141913.USD","IE00B19Z9P08.USD","GB00BDT5M118.USD","LU0289739699.SGD","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","IE0009355771.USD","BIIB","LU0122379950.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","LU0471298694.HKD","LU0006306889.USD","IE0004445239.USD","IE00B894F039.SGD","LU1061106388.HKD","LU0882574055.USD","LU0256863811.USD","LLY","BK4534","IE00BJT1NW94.SGD","BK4532","LU0109391861.USD","LU1035775433.USD","LU1093756168.USD","IE00B1BXHZ80.USD","LU0385154629.USD","SRRK","BK4585"],"gpt_icon":0},{"id":"2470578937","title":"Ptc Therapeutics, Inc.盘中异动 股价大涨5.13%报38.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470578937","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470578937?lang=zh_cn&edition=full","pubTime":"2024-09-27 00:46","pubTimestamp":1727369185,"startTime":"0","endTime":"0","summary":"北京时间2024年09月27日00时46分,Ptc Therapeutics, Inc.股票出现波动,股价快速拉升5.13%。Ptc Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.06%。其相关个股中,Pasithea Therapeutics Corp.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大,Pasithea Therapeutics Corp.、Nucana Plc、Kintara Therapeutics, Inc.较为活跃,换手率分别为4652.96%、165.43%、110.52%,振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Pasithea Therapeutics Corp.,振幅分别为72.58%、42.53%、42.13%。Ptc Therapeutics, Inc.公司简介:PTC Therapeutics Inc 是一家生物制药公司,专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240927004625a1dcc7ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240927004625a1dcc7ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0109394709.USD","BK4139","LU0889565916.HKD","PTCT","LENZ"],"gpt_icon":0},{"id":"2460350244","title":"Ptc Therapeutics, Inc.2024财年第二财季实现净利润-99.18百万美元,同比增加50.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460350244","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460350244?lang=zh_cn&edition=full","pubTime":"2024-08-17 00:00","pubTimestamp":1723824035,"startTime":"0","endTime":"0","summary":"8月17日,Ptc Therapeutics, Inc.公布财报,公告显示公司2024财年第二财季净利润为-99.18百万美元,同比增加50.16%;其中营业收入为1.87亿美元,同比减少12.62%,每股基本收益为-1.29美元。从资产负债表来看,Ptc Therapeutics, Inc.总负债28.97亿美元,其中短期债务16.01百万美元,资产负债比为0.67,流动比率为2.23。机构评级:截至2024年8月17日,当前有12家机构对Ptc Therapeutics, Inc.目标价做出预测,其中目标均价为38.75美元,其中最低目标价为26.00美元,最高目标价为64.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005539f31b105&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005539f31b105&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PTCT"],"gpt_icon":0},{"id":"2458595146","title":"Ptc Therapeutics, Inc.盘中异动 股价大跌5.73%报30.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458595146","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458595146?lang=zh_cn&edition=full","pubTime":"2024-08-09 21:31","pubTimestamp":1723210269,"startTime":"0","endTime":"0","summary":"北京时间2024年08月09日21时31分,Ptc Therapeutics, Inc.股票出现波动,股价大幅跳水5.73%。Ptc Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.32%。其相关个股中,Pasithea Therapeutics Corp C/Wts 12/08/2026 、Third Harmonic Bio, Inc.、Adma Biologics Inc涨幅较大,Conduit Pharmaceuticals Inc.、Cns Pharmaceuticals, Inc.、Entero Therapeutics Inc.较为活跃,换手率分别为32.28%、5.26%、4.90%,振幅较大的相关个股有Brainstorm Cell Therapeutics Inc.、Enliven Therapeutics, Inc.、Relmada Therapeutics, Inc.,振幅分别为10.21%、9.58%、9.57%。Ptc Therapeutics, Inc.公司简介:PTC Therapeutics Inc 是一家生物制药公司,专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809213109958bfd6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809213109958bfd6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0109394709.USD","BK4139","LU0889565916.HKD","PTCT","LENZ"],"gpt_icon":0},{"id":"2457775287","title":"Ptc Therapeutics, Inc.盘中异动 早盘快速跳水5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457775287","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457775287?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:40","pubTimestamp":1722865259,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时40分,Ptc Therapeutics, Inc.股票出现波动,股价大幅下挫5.37%。Ptc Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为2.18%。其相关个股中,Zevra Therapeutics, Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Cervomed Inc.涨幅较大,Cns Pharmaceuticals, Inc.、Dermata Therapeutics, Inc.、Senti Biosciences, Inc.较为活跃,换手率分别为1093.28%、54.23%、14.18%,振幅较大的相关个股有Cns Pharmaceuticals, Inc.、Alterity Therapeutics Limited、60 Degrees Pharmaceuticals, Inc.,振幅分别为21.59%、20.00%、17.81%。Ptc Therapeutics, Inc.公司简介:PTC Therapeutics Inc 是一家生物制药公司,专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805214059941fe364&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805214059941fe364&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTCT","BK4139","LU0320765992.SGD","LENZ","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2452439114","title":"Ptc Therapeutics, Inc.盘中异动 股价大跌5.12%报32.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452439114","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452439114?lang=zh_cn&edition=full","pubTime":"2024-07-19 00:02","pubTimestamp":1721318553,"startTime":"0","endTime":"0","summary":"北京时间2024年07月19日00时02分,Ptc Therapeutics, Inc.股票出现波动,股价大幅跳水5.12%。Ptc Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为2.30%。其相关个股中,Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Onconetix, Inc.、Silo Pharma, Inc.涨幅较大,Silo Pharma, Inc.、Salarius Pharmaceuticals, Inc.、Onconetix, Inc.较为活跃,换手率分别为2267.53%、2161.83%、1187.04%,振幅较大的相关个股有Silo Pharma, Inc.、Salarius Pharmaceuticals, Inc.、Onconetix, Inc.,振幅分别为93.33%、91.50%、86.24%。Ptc Therapeutics, Inc.公司简介:PTC Therapeutics Inc 是一家生物制药公司,专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190002349681e1e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190002349681e1e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU0889565916.HKD","PTCT","LENZ","LU0320765992.SGD","BK4139"],"gpt_icon":0},{"id":"2451899229","title":"坎托菲茨杰拉德公司:重申PTC Therapeutics(PTCT.US)评级,由增持调整至增持评级, 目标价由62.00美元调整至62.","url":"https://stock-news.laohu8.com/highlight/detail?id=2451899229","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451899229?lang=zh_cn&edition=full","pubTime":"2024-07-16 21:12","pubTimestamp":1721135528,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PTCT","LU0320765992.SGD","BK4576","LU1951200564.SGD","LU2506952337.HKD","BK4554","BK4139","BK4023","LU0109394709.USD","LU2506952410.USD","LU0889565916.HKD","BK4585","LENZ","LU1923623000.USD","LU1951198990.SGD","LU2477742899.HKD","LU1721428347.USD","PTC","BK4588"],"gpt_icon":0},{"id":"2448990541","title":"坎托菲茨杰拉德公司:维持PTC Therapeutics(PTCT.US)评级,由增持调整至增持评级, 目标价由52.00美元调整至62.","url":"https://stock-news.laohu8.com/highlight/detail?id=2448990541","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448990541?lang=zh_cn&edition=full","pubTime":"2024-07-01 21:03","pubTimestamp":1719838999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BK4576","BK4023","PTCT","LU0109394709.USD","LU1923623000.USD","LU1951198990.SGD","BK4139","LU0320765992.SGD","LU0889565916.HKD","LENZ","LU1951200564.SGD","BK4554","BK4585","PTC"],"gpt_icon":0},{"id":"2448952768","title":"美国研究综述-AT&T, ATI, 加利福尼亚资源公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2448952768","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448952768?lang=zh_cn&edition=full","pubTime":"2024-07-01 15:23","pubTimestamp":1719818605,"startTime":"0","endTime":"0","summary":" 路透7月1日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价,其中包括 AT&T、ATI 和加州资源公司。要闻 * AT&T Inc :摩根大通将其股票列入美国分析师关注名单 * ATI Inc :摩根大通将其股票从美国分析师关注名单中删除 * 加州资源公司 :Gerdes Energy Research将其评级从 \"买入 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KNTK","SM","LU0109394709.USD","CENT","TSHA","LU1621767737.EUR","IE00B7SZLL34.SGD","CRC","BK4585","WBA","BK4187","LU0321505439.SGD","BK4505","BK4144","LU1621767810.EUR","T","ATI","BK4207","BK4561","BK4018","HXL","LU1621768115.EUR","SPB","ACCD","BK4588","CHRS","LU2065732104.USD","ELAN","RCKT","BK4507","BK4139","PTCT","BK4211","BK4562","ILMN","BK4196","LU0889565916.HKD","OVV","LU0053671581.USD","APLS","RIVN","BK4213","BK4589","EQT","INSM","IE00BSNM7G36.USD","NKLA","NOG","FCNCA","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2446880056","title":"Ptc Therapeutics, Inc.股价重挫15.20% 市值跌3.43亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446880056","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446880056?lang=zh_cn&edition=full","pubTime":"2024-06-28 21:31","pubTimestamp":1719581505,"startTime":"0","endTime":"0","summary":"北京时间2024年06月28日21时31分,Ptc Therapeutics, Inc.股票出现波动,股价快速下跌15.20%。Ptc Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.03%。其相关个股中,Nls Pharmaceutics Ltd C/Wts 02/02/2026、Revolution Medicines Inc C/Wts 17/12/2026 、180 Life Sciences Corp C/Wts 07/11/2025涨幅较大,Clearmind Medicine Inc.、Carisma Therapeutics, Inc.、Geovax Labs, Inc.较为活跃,换手率分别为191.61%、17.54%、15.43%,振幅较大的相关个股有Clearmind Medicine Inc.、Carisma Therapeutics, Inc.、Nanobiotix,振幅分别为13.43%、10.16%、8.84%。Ptc Therapeutics, Inc.公司简介:PTC Therapeutics Inc 是一家生物制药公司,专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406282131459f7138f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406282131459f7138f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0889565916.HKD","BK4139","LENZ","LU0109394709.USD","PTCT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ptcbio.com","stockEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0908},{"period":"3month","weight":0.2559},{"period":"6month","weight":0.153},{"period":"1year","weight":0.9838},{"period":"ytd","weight":0.5562}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ptc Therapeutics, Inc.于1998年3月31日注册成立为一家特拉华州公司。 PTC Therapeutics股份有限公司是一家生物制药公司,专注于用于转录后控制过程中的口服药,专有的小分子药物的发现和开发。同时该公司的研发计划针对于多个治疗领域,公司特别专注于孤儿和超孤儿混乱疾病的治疗的开发和商业化。公司主导的候选产品是ataluren,该产品用于治疗过程中所出现的一种被称为无义突变基因突变的遗传性疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.108578},{"month":2,"riseRate":0.545455,"avgChangeRate":-0.006897},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.072507},{"month":4,"riseRate":0.545455,"avgChangeRate":0.029187},{"month":5,"riseRate":0.545455,"avgChangeRate":0.027228},{"month":6,"riseRate":0.545455,"avgChangeRate":0.056583},{"month":7,"riseRate":0.636364,"avgChangeRate":0.023181},{"month":8,"riseRate":0.75,"avgChangeRate":0.072316},{"month":9,"riseRate":0.5,"avgChangeRate":0.021861},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.090754},{"month":11,"riseRate":0.666667,"avgChangeRate":0.122064},{"month":12,"riseRate":0.636364,"avgChangeRate":0.045178}],"exchange":"NASDAQ","name":"PTC Therapeutics Inc.","nameEN":"PTC Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PTC Therapeutics Inc.(PTCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PTC Therapeutics Inc.,PTCT,PTC Therapeutics Inc.股票,PTC Therapeutics Inc.股票老虎,PTC Therapeutics Inc.股票老虎国际,PTC Therapeutics Inc.行情,PTC Therapeutics Inc.股票行情,PTC Therapeutics Inc.股价,PTC Therapeutics Inc.股市,PTC Therapeutics Inc.股票价格,PTC Therapeutics Inc.股票交易,PTC Therapeutics Inc.股票购买,PTC Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PTC Therapeutics Inc.(PTCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}